Results 261 to 270 of about 34,079 (294)

Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life. [PDF]

Dermatol Ther (Heidelb)
Augustin M, Barker J, Conrad C, Jullien D, Carrascosa JM, Reddy J, Amouzadeh H, Colgan S, Zou H, Mrowietz U.   +9 more
europepmc   +1 more source

The Relationship Between Chronic Pruritus, Attention-Deficit/Hyperactivity Disorder, and Skin Picking-A Case Series and Narrative Review. [PDF]

J Clin Med
Loos E, Sekar S, Rosin C, Navarini AA, Schwale C, Schaefert R, Müller S.   +6 more
europepmc   +1 more source

Unpacking the Itch Score: A Critical Examination of Routine Itch Measurement in Dermatology Practice. [PDF]

JID Innov
Majid S, Feldman SR.
europepmc   +1 more source

A Study on Scratching Behavior Characteristics in Patients With Various Types of Chronic Pruritus. [PDF]

Allergy Asthma Immunol Res
Lee JH, Na CH, Ryoo JH, Chae SY, Kim JH, Park DY, Bang JS, Kim E, Kwak JH, Kang DH, Lew BL, Jang YH.   +11 more
europepmc   +1 more source

Itch

, 1995
openaire   +1 more source

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.

JAMA Dermatol
McMichael A, Shahriari M, Stein Gold L, Alkousakis T, Choi O, Bhutani T, Rodriguez AO, Tyring SK, Chan D, Rowland K, Albrecht L, Lynde C, Yadav G, Yeung J, Park-Wyllie L, Ma T, Jeyarajah J, Gao LL, Smith S, Moore AY, Vashi N, Kindred C, Grimes P, Desai SR, Taylor SC, Alexis A, VISIBLE Trial Investigators.   +26 more
europepmc   +1 more source